Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001641172-25-000208
Filing Date
2025-03-24
Accepted
2025-03-24 08:30:38
Documents
69
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 form10-k.htm   iXBRL 10-K 2728933
2 ex23-1.htm EX-23.1 3357
3 ex31-1.htm EX-31.1 12275
4 ex31-2.htm EX-31.2 12189
5 ex32-1.htm EX-32.1 7040
6 ex32-2.htm EX-32.2 8089
7 form10-k_001.jpg GRAPHIC 20468
8 form10-k_002.jpg GRAPHIC 90281
9 form10-k_003.jpg GRAPHIC 87277
10 form10-k_004.jpg GRAPHIC 93606
  Complete submission text file 0001641172-25-000208.txt   9885958

Data Files

Seq Description Document Type Size
11 XBRL SCHEMA FILE lixt-20241231.xsd EX-101.SCH 51105
12 XBRL CALCULATION FILE lixt-20241231_cal.xml EX-101.CAL 43043
13 XBRL DEFINITION FILE lixt-20241231_def.xml EX-101.DEF 287888
14 XBRL LABEL FILE lixt-20241231_lab.xml EX-101.LAB 477079
15 XBRL PRESENTATION FILE lixt-20241231_pre.xml EX-101.PRE 383576
71 EXTRACTED XBRL INSTANCE DOCUMENT form10-k_htm.xml XML 1251851
Mailing Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733
Business Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733 310 203 2902
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Filer) CIK: 0001335105 (see all company filings)

EIN.: 202903526 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-39717 | Film No.: 25762332
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)